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Abstract
Purpose: A relevant challenge for the improvement of clear cell renal cell carcinoma management could derive from the
identification of novel molecular biomarkers that could greatly improve the diagnosis, prognosis, and treatment choice of these
neoplasms. In this study, we investigate whether quantitative parameters obtained from computed tomography texture analysis
may correlate with the expression of selected oncogenic microRNAs. Methods: In a retrospective single-center study, multi-
phasic computed tomography examination (with arterial, portal, and urographic phases) was performed on 20 patients with clear
cell renal cell carcinoma and computed tomography texture analysis parameters such as entropy, kurtosis, skewness, mean, and
standard deviation of pixel distribution were measured using multiple filter settings. These quantitative data were correlated with
the expression of selected microRNAs (miR-21-5p, miR-210-3p, miR-185-5p, miR-221-3p, miR-145-5p). Both the evaluations
(microRNAs and computed tomography texture analysis) were performed on matched tumor and normal corticomedullar tis-
sues of the same patients cohort. Results: In this pilot study, we evidenced that computed tomography texture analysis has
robust parameters (eg, entropy, mean, standard deviation) to distinguish normal from pathological tissues. Moreover, a higher
coefficient of determination between entropy and miR-21-5p expression was evidenced in tumor versus normal tissue. Inter-
estingly, entropy and miR-21-5p show promising correlation in clear cell renal cell carcinoma opening to a radiogenomic strategy
to improve clear cell renal cell carcinoma management. Conclusion: In this pilot study, a promising correlation between
microRNAs and computed tomography texture analysis has been found in clear cell renal cell carcinoma. A clear cell renal cell
carcinoma can benefit from noninvasive evaluation of texture parameters in adjunction to biopsy results. In particular, a promising
correlation between entropy and miR-21-5p was found.
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Introduction
Clear cell renal cell carcinoma (ccRCC) is a group of
chemotherapy-resistant tumors representing 2% to 3% of all
adult malignancies and is the third most common urological
cancer after prostate and bladder cancer. There is a wide pre-
valence of clear cell histotype (ccRCC, 80%-90% of all RCCs),
which has, also, the highest mortality rate.1,2 Deeper molecular
characterization could improve ccRCC diagnosis and manage-
ment, as well as prognosis and treatment choice. In this sce-
nario, microRNAs (miRNAs) are emerging as interesting
biomarkers for several tumors.3,4 They are small noncoding
RNAs that have an important role in the regulation of carcino-
genesis. The miRNAs expression is indeed deregulated in neo-
plastic tissue compared with corresponding normal tissue.
MicroRNAs may regulate crucial break points during carcino-
genesis.5,6 Recently, they have been addressed as part of
ccRCC tumorigenesis and progression,7,8 so that a “miRNA
signature” in ccRCC has been described and significantly cor-
related with patients’ outcome.9,10 miR-21 and miR-210, as
well as miR-185 and miR-221, showed functional relevance
for ccRCC tumorigenesis.11,12
The grade of expression of miRNAs is cancer- and tissue-
specific; for this reason, the expression profile of miRNAs in
ccRCC can be helpful to differentiate healthy from pathologi-
cal tissue, to identify slightly differentiated cancers that would
otherwise be undetermined with the use of conventional histol-
ogy and immunohistochemistry, and, lastly, to recognize
tumors with different histotypes within the same organ.9 Fur-
ther, we tried to understand if ccRCC-associated miRNAs had
a corresponding phenotype in radiological examinations
(radiophenotype), looking for a connection between genotype
and radiophenotype.
Radiogenomics refers to the correlation between cancer
imaging features and gene expression: The most interesting
results have been obtained in onco-imaging field. Recently,
some authors have evaluated the correlation between
the imaging characteristics and molecular features of
malignancies.13-15
An emerging potentially useful imaging biomarker is com-
puted tomography (CT) tumor texture analysis (CTTA), which
has shown promising results in predicting patient outcome,
overall survival, and response to therapy for multiple tumors,
including RCC.13,16
Computed tomography texture analysis is a quantitative
technique that allows to characterize the heterogeneity of a
lesion inside a region of interest (ROI) by analyzing the distri-
bution and relationship of pixel gray levels using both unfil-
tered and frequency-filtered images, deriving quantitative
texture parameters based on attributes of the pixels and the
image histogram.16
To the best of our knowledge, a possible correlation between
CT texture parameters and miRNAs expression in ccRCC was
not investigated yet. To this end in this study, we investigate
whether quantitative parameters obtained from CTTA correlate
with different grades of expression of miRNAs in patients
affected by ccRCC.
Material and Methods
Study Population
We designed a retrospective single-center study conducted on
patients who had contrast-enhanced computed tomography
(CECT) of the abdomen and pelvis for suspected ccRCC
between April 1, 2014, and June 1, 2016. Patients’ recruitment
was based on the Standards for Reporting of Diagnostic Accu-
racy initiative as reported in accrual flowchart (Figure 1). Insti-
tutional review board approved the study protocol and written
consent was acquired from each patient. Clinical indications
for CT included (1) clinical suspicion for ccRCC based on the
patient’s clinical history and/or elevated tumor markers levels
or (2) patients known to have a suspicious renal lesion on the
basis of the results of prior imaging studies, such as ultrasono-
graphy, unenhanced CT, or magnetic resonance imaging
(MRI). Patients characteristics are summarized in Table 1.
No authors are employees of or consultants for industry or
had control of inclusion of any data and information that could
represent a conflict of interest. There was no industry support
specifically for this study.
Forty-five consecutive patients who underwent CECT of the
abdomen and pelvis for suspected ccRCC between April 1,
2014, and June 1, 2016, were primarily included.
Ten patients were considered not eligible for this study due
to (1) the CT examination resulted in no kidneys lesions; (2)
patients underwent previously chemotherapy, radiotherapy, or
immunotherapy; (3) too small lesion for good CTTA (<2 cm),
(4) inadequate image quality due to suboptimal injection tech-
nique, poor timing for the acquisition of the urographic phase,
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or deviations from the routine CT protocol (eg, inappropriate
selection of kV or reconstruction kernel by the CT technolo-
gist). Based on CT and clinical presurgery evaluations, we
could include 35 patients, 8 of which were proved to have
benign lesions (basing on other imaging evaluations, follow-
up, or percutaneous biopsy). Finally, 2 patients with suspicious
RCC on the base of CT characteristics refused biopsy or sur-
gery due to old age and suboptimal global clinical conditions.
Among these 27 patients, 6 underwent biopsy and 26 direct
surgeries (nephrectomy or partial nephrectomy based on tumor
size). After histopathological examination, only 21 ccRCC
were found; 1 of them was not eligible for the study because
of no complete miRNAs extraction for tumor and matched
normal tissue.
Our final study population included 20 patients (14 males, 6
females; mean age 65 + 13 years, range 35-87 years; mean
body mass index 27 kg/m2 + 4.37; range 20.8-40.3 kg/m2)
with 20 ccRCC suitable for CTTA examination and miRNAs
extraction (Figure 1 and Table 1).
Histopathological Analysis, RNA Extraction,
and MiRNA Expression Analysis
Eight samples of fresh-frozen (FF) tissues from 8 ccRCC lesions
were analyzed and homogenized by gentle dissociator (Miltenyi
Biotec, USA) in 700 mL of Qiazol (Qiagen, Chatsworth, Califor-
nia); RNA was extracted using the manufacturer’s instructions.
A cohort of 12 ccRCC formalin-fixed paraffin-embedded
(FFPE) tissue samples from 12 patients was analyzed. RNA
was extracted using the miRneasy FFPE kit (Qiagen) following
the manufacturer’s instructions.
For eachpatient, amatched normal tissue samplewas collected.
For both cohorts, the concentration and purity of total RNA were
assessed using a Nanodrop 1000 spectrophotometer (Nanodrop
Technologies, Wilmington, Delaware). RNA from FF tissues and
FFPE tissues showed comparable quality. A quantity of 150 ng of
total RNA was reverse transcribed in 8 mL using miScript II real-
time (RT) kit (Qiagen), and 1mLof complementaryDNA (cDNA)
dilution (1:4) was used for quantitative RT polymerase chain
Figure 1. Flowchart of patients’ selection.
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reaction (PCR) experiments. A PCR quantification analysis of the
SCARNA17 SNORD61, SNORD68, RNU6-2, andmiRNAs such
as miR-21-5p, miR-210-3p, miR-185-5p, miR-221-3p, and miR-
145-5p was performed using the miScript SYBR Green PCR kit
(Qiagen) with the miScript Primer assay Hs-SCARNA17
(#MS00014014), SNORD61 (#MS00033705), SNORD68
(#MS00033712), RNU6B-2 (#MS00033740), Hs-miR-21-5p
(#MS00009079), Hs-miR-210-3p (#MS00003801), Hs-miR-
185-5p (#MS00003647), Hs-miR-221-3p (#MS00003857), and
Hs-miR-145-5p (#MS00003528; Qiagen).
The expression analyses of RNU19 and RNU66 were per-
formed using TaqMan miRNA RT assay and TaqMan miRNA
assays (RNU19 #001003 and RNU66 #001002; Applied Bio-
systems, Foster City, California) according to the manufactur-
er’s protocol. All reactions were performed in duplicate. Data
were analyzed by quantification relatively to a standard curve.
The standard curve was prepared with serial dilutions of a
reference cDNA obtained from RNA extracted from a tumor
sample. Z scores were calculated for all expression values to
standardize the data. Subsequently, z score values of RNU66,
RNU19, and SCARNA17 were averaged and used to normalize
the expression values of each miRNA in FFPE samples,
whereas z score values of SNORD61, SNORD68, and
RNU6-2 were averaged and used to normalize the expression
values of each miRNA in FF samples (Table 2).
MDCT Acquisition Protocol
All scans were performed with a 64-row multiple-detector
computed tomography (MDCT) scanner (Lightspeed VCT,
GE Medical Systems, Waukesha, Wisconsin) using the follow-
ing parameters: kV, 120; beam pitch, 1.375:1; detector config-
uration, 64 mm  0.625 mm; and reconstructed section
thickness, 1.25 mm.
A z-axis tube current modulation was used, with a noise
index of 28 (min/max mA: 200/600), which was recommended
by the manufacturer for standard abdominal CT in all cases. All
examinations were performed using a multiphase MDCT pro-
tocol (Table 3).
All patients received an average of 120 mL of an intrave-
nous nonionic contrast medium (CM) with an iodine concen-
tration of 350 mg iodine/mL (Iomeprol, Iomeron 350; Bracco,
Milan, Italy). The bolus of CM was injected through an 18 or
20 gauge cannula inserted into an antecubital vein using a dual-
chamber peristaltic injector (CT Expre`s, Bracco, Milan, Italy)
at a flow rate of 3.5 mL/s.
All patients were positioned supine with head first on the
scanning table. The scanning protocol started with the acquisi-
tion of anteroposterior and lateral digital localizer radiographs.
The acquisitions of the abdomen and pelvis were performed in
the craniocaudal direction after iodine intravenous injection of
CM in arterial, portal, and urographic phases.
A bolus tracking technique was used to minimize the influ-
ence of cardiac output; CM detection was monitored in an ROI
placed in the aorta at the level of the diaphragm; the threshold
for the start of the scan was set at 100 HU. A late arterial phase
was acquired 18 seconds after reaching the threshold; a portal
phase 35 seconds after the end of arterial phase; an urographic
phase was acquired after 12 minutes.
Image Reconstruction
Imaging reconstructions were obtained using 40% of an itera-
tive reconstruction algorithm (ASiR, GE Healthcare, Milwau-
kee, Wisconsin) as recommended by the manufactory. The
use of 40% iterative reconstruction algorithm and 60% of
filtered back projection algorithm (standard algorithm) allows
to obtain high image quality, with low image noise, even
when a low-radiation dose acquisition protocol is used, as in
our study.
Images were reconstructed using a medium-smooth kernel
(Q30) at 1.25 mm reconstructed section thickness (Table 3).
Imaging Data Analysis
All analyses were performed using a commercially available
CTTA research software platform (version 1.1; TexRAD Ltd,
Somerset, United Kingdom) on a dedicated workstation. Com-
puted tomography texture analysis was performed on 20
ccRCCs drawing manually 2 different polygonal ROIs at 3
different axial levels in arterial, portal, and urographic phases
(Figure 2) (1) into the lesion (including the majority of the
lesion in that plane and excluding margins) and (2) in the
normal parenchyma of the kidney, adjacent to the tumor,
including cortical and medullar layers.
Table 1. Patient Clinical and Histological Characteristics.
Patient Demographics and Characteristics at Diagnosis
Number of patients 20
Age, years 65 + 3
Gender
Male 14
Female 6
Body mass index, kg/m2 27 + 4.37
Serum creatinine, mg/dL 1.45+ 0.72
Smoking habit
Yes 13
No 7
Pathological tumor stage (pT)
pT1a 11
pT1b 4
pT2a 1
pT2b 1
pT3 3
Surgical procedure
Tumorectomy 7
Radical nephrectomy 13
Clear cell tumor grade
1 3
2 15
3 2
Tumor maximum diameter, cm 4.2+ 2.4
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All images were reviewed, and slices were selected by 2
readers (radiologist with 10 years of experience and radiology
resident with 3 years of experience on abdominal imaging).
The technique consisted of a preliminary filtration step,
followed by quantification of the texture within the filtered
images.
The filtration step comprised Laplacian of Gaussian spatial
band-pass filter used to produce multiple series of derived
images extracting and enhancing features at different anatomi-
cal spatial scales; this resulted in a series of derived images
from fine to coarse texture within an ROI identified with
“spatial scaling factor” (SSF). The scale was selected by tuning
the filter parameter between SSF0 and SSF2.0, where SSF1.0
indicates fine texture (features of approximately 2 pixels in
width), SSF1.5, SSF1.8, and SSF2.0 indicate degrees of
medium textures (features of approximately 6, 8, and 10 pixels
in width, respectively).
This is followed by quantification of statistical parameters
in a histogram-based statistical approach (first-order, second-
order, or higher order parameters). The software output
includes mean pixel attenuation (M, mean), standard deviation
of the pixel distribution histogram (standard deviation [SD],
dispersion from the mean), entropy (E, irregularity in terms
of randomness of distribution of pixels), mean of positive pix-
els (MPP), skewness of the pixel histogram (S, asymmetry),
kurtosis (K, sharpness) of the pixel histogram, and the percent-
age of positive pixels; all these histogram-based parameters are
provided for each SSF.
Statistical Analysis
All data were described as mean+ SD. Computed tomography
texture analysis was performed for each of the 6 parameters at
each SSF (in number of 5) and for all postcontrast CT phases
acquired (ie, normal renal parenchyma, arterial phase, portal
phase, and urographic phase), with a total of 120 variables.
A matrix of data on MatLab have been elaborated from 5
different miRNAs (miR-145-5p, miR-185-5p, miR-221-3p,
miR-21-5p, and miR-210-3p), 6 texture parameters (mean,
SD, entropy, MPP, skewness, and kurtosis) in 5 different SSFs
(SSF0, SSF1, SSF1.5, SSF1.8, and SSF2.0). All data were
elaborated for normal kidney parenchyma and for 3 different
ROIs on tumor volume, finally producing a total of more than
500 graphics of correlation. Normality of each continuous vari-
able was tested with Z test. Differences between normal tissue
and tumor in all miRNAs expression and all CTTA parameters
were assessed using paired Student t test. First step of statistical
analysis was aimed to assess statistically significant differences
between the 2 groups of lesions’ samples: FFPE and FF.
Differences in the evaluations of CTTA parameters between
the 2 operators were calculated (interobserver agreement with
Cohen k, with k  .40 poor agreement, k ¼ .40-.75 good
agreement, k  .76 excellent agreement).
Secondary, all lesions were evaluated all together, since no
statistically significant difference in miRNAs expression was
found between the 2 groups and between the 2 operators for
CTTA. In addition, statistically significant difference was
assessed for (1) miRNA normal tissue versus tumor samples
and (2) CTTA parameters in normal tissue versus tumor
samples.
For comparison of miRNA versus CTTA parameters was
then used: (1) the Pearson correlation coefficient (r): r was
interpreted as follows: A negative value or less than 0.20 indi-
cated poor agreement; a value of 0.21 to 0.40, fair agreement; a
value of 0.41 to 0.60, moderate agreement; a value of 0.61 to
0.80, substantial agreement; and a value of 0.81 to 1.00, almost
perfect agreement; (2) the coefficient of determination (R2) in a
polynomial interpolation graphic type of order 2. R2 quantifies
the amount of variance of the variable that is explained by the
selected polynomial with respect to the average of the data. R2
was interpreted as follows: A negative value or less than 0.20
indicated poor agreement; a value of 0.21 to 0.40, fair agree-
ment; a value of 0.41 to 0.60, moderate agreement; a value of
0.61 to 0.80, substantial agreement; and a value of 0.81 to 1.00,
almost perfect agreement.
Table 3. CT Acquisition and Reconstruction Parameters.
MDCT Parameters
Detector configuration, mm 64  0.625
Tube voltage, kV 120
Automatic exposure control (AEC) On
Current tube modulation, mAs 200/600
Noise index 28
Field of view, cm 50
Rotation time, seconds 0.5
Pitch 1.375
Reconstruction kernel Medium-Smooth
Reconstruction algorithm Q30
Iterative reconstruction algorithm, % 40
Slice thickness, mm 1.25
Abbreviations: CT, computed tomography; MDCT, multiple-detector com-
puted tomography.
Table 2. Evaluation of MicroRNAs Levels in Patients With ccRCC.
Mean Values MicroRNAs Levels (+SD)
miR-21-5p miR-210-3p miR-221-3p miR-185-5p miR-145-5p
Normal tissue 0.60 (+0.51) 1.18 (+0.94) 0.71 (+0.32) 1.08 (+0.96) 1.04 (+0.33)
ccRCC 0.94 (+0.61) 1.57 (+1.31) 1.13 (+0.74) 1.03 (+0.47) 1.14 (+0.65)
P value <.05 <.05 <.05 >.05 >.05
Abbreviations: ccRCC, clear cell renal cell carcinoma; SD, standard deviation.
Marigliano et al 5
For all comparisons, statistical significance was assumed to
be P < .05. All statistical analyses were performed using a
commercially available statistical software package SPSS ver-
sion 21.0 (SPSSInc, Chicago, Missouri).
Results
A total of 20 matched ccRCC and adjacent normal tissue sam-
ples were collected and analyzed for the expression of miR-21-
5p, miR-210-3p, miR-185-5p, miR-221-3p, and miR-145-5p
included in our previous study on ccRCC.17 According to pre-
vious reports, miR-21-5p, miR-210-3p, and miR-221-3p
resulted significantly upregulated in ccRCC (0.94 + 0.61,
1.57 + 1.32, and 1.13 + 0.74, respectively) versus normal
(0.60 + 0.52, 1.18 + 0.94, and 0.71 + 0.33, respectively)
tissues (P < .05; Table 2). miR-185-5p and miR-145-5p did not
show any statistically significant difference between tumor and
normal tissues (Table 2).
Regarding CTTA acquisition, all scans were performed with
a 64-row MDCT scanner following acquisition and reconstruc-
tion parameters summarized in Table 3. No differences were
found between the 2 operators in collected CTTA parameters
(k ¼ .84). The analyses shown below were elaborated choosing
data from the best operator results (best correlations found).
When considering texture parameters alone, differences between
healthy and pathological tissue within the same SSF and the
same contrast phase were consistent and statistically significant
for the majority of parameters (entropy, MPP, SD, and mean)
when a medium texture filter setting (SSF1 or SSF1.5) was used
(P < .05); for these parameters, we observed a statistically sig-
nificant difference between normal tissue ROIs and pathological
tissues, in all contrast phases (Table 4 and Figure 3).
Figure 2.A 58-year-old man with a large ccRCC on the left side. A-B, Portal venous phase contrast-enhanced transverse (A) and coronal (B) CT
images showing tumor (arrows). C, Texture analysis image showing ROI (blue line) outlining cancer. D-F, Color texture overlays of cancer
outlined by an ROI (blue line) showing images with a fine filtering (SSF1) (D), medium filtering (SSF1.5) (E), and coarse filtering (SSF2) (F).
ccRCC indicates clear cell renal cell carcinoma; ROI, region of interest; SSF, spatial scaling factor.
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Moreover, comparing different contrast phases within the
same SSF or the same contrast phase among different SSF,
no significant differences were found in particular at medium
filters (SSF 1.5–1.8–2.0). In specific entropy, values in the
arterial phase in normal tissue were 4.66 + 0.21 (SF1), 4.71
+ 0.21 (SF1.5), 4.72+ 0.19 (SF1.8), and 4.73+ 0.19(SF2.0),
while in tumor ROI entropy was 5.67 + 0.41 (SF1), 5.76 +
0.40 (SF1.5); 5.79+ 0.39 (SF1.8), and 5.80+ 0.40 (SF 2.0).
MicroRNAs expression in normal tissue didn’t correlate
significantly with any CTTA parameter (P > .05). Analysis
of tumor samples evidenced only a trend of positive correlation
between miRNAs (miR-21-5p and miR-210-3p) and some
CTTA parameters. The best trends were found when delta of
percent (%D) of expression between healthy tissue and patho-
logical tissue were used to express our data (Table 5).
When comparing CT texture parameters and miRNAs
expression in a polynomial interpolation graphic type of
order 2, we found a dispersion of data in the graphics of
comparison, showing poor agreement with miRNAs expres-
sivity for most of the parameters (data shown in Supple-
mentary material).
Interestingly, entropy showed the best agreement between
miRNAs expression and CT texture parameters. For example,
as shown by nonlinear graphic analysis between%D of miRNA
expression (matched tumor vs normal tissues) and entropy val-
ues (Figure 3A), in tumor tissues a higher coefficient of deter-
mination is present between entropy and the %D of miR-21-5p
expression (R2 ¼ 0.25) compared to normal tissues (R2 ¼ 0.15;
Figure 3A). On the contrary, a similar effect was not observed
for miR-210-3p (R2 ¼ 0.025 in tumor vs R2 ¼ 0.014 in normal;
Figure 3B). These results were confirmed using all SSF and all
postcontrast phases (data not shown). Moreover, a nonlinear
graphic analysis between %D of miR-21-5p expression
(matched tumor vs normal tissues) and skewness values didn’t
show any correlation (R2 ¼ 0.0020 in tumor vs R2 ¼ 0.072 in
normal; data not shown). Analyzing data, we recognized 4
patients with particularly increased miR-21-5p expression in
tumor versus normal tissues but only slight increase in entropy
values (as compared to normal tissue): Their texture parameters
were not far from the median values of the texture parameters
of the other patients. Interestingly, excluding them from the
analysis, we found again that normal tissue entropy was not
related to miR-21-5p (R2¼ 0.17), while an excellent relation of
entropy in tumor samples with miR-21-5p was found (R2 ¼
0.64; Figure 3C).
Discussion
Nowadays, the evaluation of a renal lesion using CT or MRI is
based on the radiologist’s 2-dimensional examination of lesion
morphology and enhancement, and this routinely determines
subsequent patient management. Both CT and MRI are the
most used imaging techniques in the staging of ccRCC before
treatment; however, this type of tumors is characterized by
genetic, epigenetic, and pathologic heterogeneity, which makes
accurate diagnosis or prognosis prediction difficult. Many
efforts have been done by radiologists and experts, looking for
imaging biomarkers to characterize tumors and manage
therapies.
Computed tomography texture analysis is a relatively new
tool with a great potential; it can be of great help for the radi-
ologist to better characterize lesions and to identify parameters
of response to treatment. However, it is still soon to consider all
done. Computed tomography texture analysis allows quantifi-
cation of lesion heterogeneity based on the distribution of pixel
intensities within an ROI.
In our study, most of CTTA parameters showed significant
differences comparing normal corticomedullar tissue with
ccRCC. Computed tomography texture analysis has robust
parameters to distinguish normal tissue from ccRCC (eg,
entropy, mean, SD). This could be of great future help for
imaging characterization of renal lesion, even in terms of
survival rates and clinical outcome. The surprising result of
not significant increase in skewness and kurtosis in our cohort
of ccRCC, in contrast with previous studies on other solid
tumors (eg, rectal or lung adenocarcinoma),18-21 supports the
fact that different tumors display different radiophenotypes
and address the attention to more research in this field,22,23
with the aim of looking for a “texture signature” typical for
every tumor type.
In the field of urological carcinoma, miRNAs are acquiring
a role as biomarkers.24-26 In particular, miRNA-21-5p is the
most overexpressed in renal cancer: It interacts with Ras
phosphoinositide-3-kinase (PI-3K)/PTEN/AKT apoptosis
pathways, so it may be considered a clinical biomarker in RCC.
In a recent publication, Petrozza et al found interesting results
on overexpression of miR-210-3p on urinary samples of
Table 4. Expression of CTTA Texture Parameters in Normal Tissue and Tumor in Arterial Phase.a
Arterial Phase SSF1.5 Normal Tissue Tumor P Value P Value Venous Phase P Value Urographic Phase
Mean 1.23 (+14.7) 23.31 (+17.38) <.001 <.05 <.05
SD 101.2 (+37.8) 120.9 (+32.7) <.05 .09 .06
Entropy 4.71 (+0.20) 5.76 (+0.40) <.001 <.05 <.05
MPP 85.39 (+38.75) 107.17 (+33.1) <.05 <.05 <.05
Skewness 0.25 (+0.42) 0.36 (+0.49) .45 .52 .30
Kurtosis 0.04 (+0.63) 1.67 (+5.50) .17 .23 .10
Abbreviations: CTTA, computed tomography texture analysis; MPP, mean of positive pixels; SD, standard deviation; SSF, spatial scaling factor.
aP values are shown for arterial, venous, and urographic phase.
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patients with ccRCC and they also prove the significant reduc-
tion in concentration of this miRNA after surgery and during
follow-up.27 This finding seems to be very interesting, opening
new doors for genetic biomarkers in ready and “easy-to-col-
lect” tissue samples.
In a radiogenomics point of view, we decided to compare
CT texture parameters and miRNAs expression profile of
ccRCC looking for correlation between them.
First, we confirmed deregulation of specific miRNAs in our
group of 20 ccRCC (miR-21-5p, miR-210-3p, miR-185-5p,
miR-145-5p, and miR-221-3p), according to what found
previously.17
Regarding the comparison between expression of miRNA
and modification of CTTA in tumor samples, a surprisingly
poor positive association was found among the majority of
them in ccRCC with poor statistical significance. Interesting
results were found comparing entropy and miR-21-5p expres-
sion: No relation was found with normal tissue, while tumor
entropy is slightly positively correlated with miR-21-5p. The
results are almost stable moving into different contrast phases
and different spatial filters, giving to the correlation more
importance.
The correlation was a bit limited by data from 4 (20%)
patients, who had a significant upregulation of miR-21-5p but
a slight increase of entropy in lesions as compared to normal
tissues. The reason why these patients showed such results in
still not clear. We couldn’t find a reasonable factor to explain
this behavior, since patients performed the same CT protocol
and their tissue samples were either FF (for 2) or FFPE (for the
others). Furthermore, they were not different neither in terms of
tumor–node–metastasis or grading, without any apparent dif-
ference in comparison with the others. The only interesting
common factor was that they were among the youngest in the
cohort of patients (<60 years of age), and this could have a role
in the significant hyperexpression of miRNAs in tumor sam-
ples. More data are needed to support this conclusion. Never-
theless, without those 4 patients, we found more significant
results with very good correlation.
Texture analysis is efficient, reproducible, and can be con-
sidered complementary to 2-dimensional imaging evaluation of
ccRCC on MDCT, because it maximizes the information
obtained from the lesion and has the potential to become a tool
for prediction of prognosis.
There are some limitations to the present study, for example,
the small number of patients. Moreover, we didn’t perform
analysis on prognostic value of the parameters because of lack
of follow-up outcome data.
Figure 3. Graphics of relation and R2 value between microRNAs and
CTTA features in ccRCC. A, Comparison between miR-21-5p
(expressed as %D normal vs tumor) and tissue entropy (SSF1). B,
Comparison between miR-210-3p (expressed as%D normal vs tumor)
and tissue entropy (SSF1). C, Comparison between miR-21-5p
(expressed as %D normal vs tumor) and tissue entropy excluding 4
patients with extremely overexpressed miR-21-5p in tumor samples
(too far from median values). ccRCC indicates clear cell renal cell
carcinoma; CECT, contrast-enhanced computed tomography; CTTA,
computed tomography texture analysis; SSF, spatial scaling factor.
Table 5. CTTA Parameters and MiRNAs Pearson Correlation (Arter-
ial Phase; SSF1.5).
Mean SD Entropy MPP Skewness Kurtosis
Normal tissue
D (%) miR-21 0.30 0.14 0.06 0.10 0.21 0.09
D (%) miR-210 0.09 0.26 0.23 0.27 0.28 0.21
Tumor
D (%) miR-21 0.24 0.07 0.16 0.007 0.04 0.09
D (%) miR-210 0.11 0.15 0.09 0.17 0.01 0.13
Abbreviations: CTTA, computed tomography texture analysis; MPP, mean of
positive pixels; SD, standard deviation; SSF, spatial scaling factor.
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Conclusion
Both miRNAs and CTTA show promising correlations in
ccRCC and no correlations with normal renal tissues. Texture
parameters, in adjunction to biopsy results, can be considered
useful tools for the noninvasive evaluation of ccRCC. In par-
ticular, our study demonstrated good correlation between
entropy and miR-21-5p, one of the most important miRNA
involved in tumorigenesis, and good correlation between tex-
ture parameters (mean and entropy) and ccRCC.
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